Atrial fibrillation is associated with high levels of monocyte-plateletaggregates and increased CD11b expression in patients with aortic stenosis

Thrombosis and Haemostasis

Volumn 115, Issue 5, 2016, Pages 993-1000

  Pfluecke, Christian ^a   Berndt, Katharina ^a   Wydra, Sandy ^a   Tarnowski, Daniel ^a   Barthel, Peggy ^a   Quick, Silvio ^a   Ulbrich, Stefan ^a   Christoph, Marian ^a   Waessnig, Nadine ^a   Speiser, Uwe ^a   Wunderlich, Carsten ^a   Poitz, David M ^a   Strasser, Ruth H ^a   Ibrahim, Karim ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Atrial fibrillation; Inflammation; Monocyte platelet aggregates; Monocytes; Stroke

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD40 LIGAND; INTERLEUKIN 6; INTERLEUKIN 8; PADGEM PROTEIN; AUTACOID; BIOLOGICAL MARKER; ITGAM PROTEIN, HUMAN;

AGED; AORTA STENOSIS; ARTICLE; ATRIAL FIBRILLATION; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SINUS RHYTHM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; AORTIC VALVE STENOSIS; BLOOD; CELL AGGREGATION; COMPLICATION; IMMUNOLOGY; MONOCYTE; PATHOLOGY; THROMBOCYTE; THROMBOSIS; VERY ELDERLY;

AGED, 80 AND OVER; AORTIC VALVE STENOSIS; ATRIAL FIBRILLATION; BIOMARKERS; BLOOD PLATELETS; CD11B ANTIGEN; CELL AGGREGATION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MONOCYTES; PLATELET ACTIVATION; PLATELET AGGREGATION; THROMBOSIS;

EID: 84964801419     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-06-0477     Document Type: Article

References (44)

1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-1420.
2. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012; 60: 2263-2270.
3. Lim HS, Willoughby SR, Schultz C, et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. J Am Coll Cardiol 2013; 61: 852-860.
4. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996; 93: 11877-11882.
5. Michelson AD, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537.
6. Burdess A, Michelsen AE, Brosstad F, et al. Platelet activation in patients with peripheral vascular disease: reproducibility and comparability of platelet markers. Thromb Res 2012; 129: 50-55.
7. Wrigley BJ, Shantsila E, Tapp LD, et al. Increased formation of monocyte-platelet aggregates in ischemic heart failure. Circ Heart Fail 2013; 6: 127-135.
8. Shantsila E, Lip GY. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. Thromb Haemost 2009; 102: 916-924.
9. Pfluecke C, Tarnowski D, Plichta L, et al. Monocyte-platelet aggregates and CD11b expression as markers for thrombogenicity in atrial fibrillation. Clin Res Cardiol 2015; Epub ahead of print.
10. Lukasik M, Dworacki G, Kufel-Grabowska J, et al. Upregulation of CD40 ligand and enhanced monocyte-platelet aggregate formation are associated with worse clinical outcome after ischaemic stroke. Thromb Haemost 2012; 107: 346-355.
11. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26: 2083-2092.
12. Conen D, Ridker PM, Everett BM, et al. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J 2010; 31: 1730-1736.
13. Lazzerini PE, Capecchi PL, Acampa M, et al. Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. Autoimmun Rev 2014; Epub ahead of print.
14. Friedrichs K, Klinke A, Baldus S. Inflammatory pathways underlying atrial fibrillation. Trends Mol Med 2011; 17: 556-563.
15. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184.
16. Friedrichs K, Adam M, Remane L, et al. Induction of atrial fibrillation by neutrophils critically depends on CD11b/CD18 integrins. PLoS One 2014; 9: e89307.
17. Saba S, Janczewski AM, Baker LC, et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiacspecific overexpression of tumor necrosis factor-{alpha}. Am J Physiol Heart Circ Physiol 2005; 289: H1456-H1467.
18. Hristov M, Weber C. Differential role of monocyte subsets in atherosclerosis. Thromb Haemost 2011; 106: 757-762.
19. Belge KU, Dayyani F, Horelt A, et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536-3542.
20. Imanishi T, Ikejima H, Tsujioka H, et al. Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris. Atherosclerosis 2010; 212: 628-635.
21. Merino A, Buendia P, Martin-Malo A, et al. Senescent CD14+CD16+ monocytes exhibit proinflammatory and proatherosclerotic activity. J Immunol 2011; 186: 1809-1815.
22. Morgan E, Varro R, Sepulveda H, et al. Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol 2004; 110: 252-266.
23. Aurigemma C, Scalone G, Tomai F, et al. Persistent enhanced platelet activation in patients with acute myocardial infarction and coronary microvascular obstruction: clinical implications. Thromb Haemost 2014; 111: 122-130.
24. Jurk K, Ritter MA, Schriek C, et al. Activated monocytes capture platelets for heterotypic association in patients with severe carotid artery stenosis. Thromb Haemost 2010; 103: 1193-1202.
25. Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost 2011; 106: 827-838.
26. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010; 30: 2357-2361.
27. van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 2009; 85: 195-204.
28. Singh MV, Davidson DC, Kiebala M, et al. Detection of circulating plateletmonocyte complexes in persons infected with human immunodeficiency virus type-1. J Virol Methods 2012; 181: 170-176.
29. Gremmel T, Ay C, Riedl J, et al. Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis. Thromb Haemost 2016; 115: 615-621.
30. Alberti S, Angeloni G, Tamburrelli C, et al. Platelet-leukocyte mixed conjugates in patients with atrial fibrillation. Platelets 2009; 20: 235-241.
31. Makowski M, Smorag I, Bissinger A, et al. Effect of sinus rhythm restoration on platelet function in patients with lone atrial fibrillation. Int J Cardiol 2014; 172: e22-e23.
32. Mitusch R, Siemens HJ, Garbe M, et al. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost 1996; 75: 219-223.
33. Hu YF, Yeh HI, Tsao HM, et al. Impact of circulating monocyte CD36 level on atrial fibrillation and subsequent catheter ablation. Heart Rhythm 2011; 8: 650-656.
34. Shinohara H, Fukuda N, Soeki T, et al. Relationship between flow dynamics in the left atrium and hemostatic abnormalities in patients with nonvalvular atrial fibrillation. Jpn Heart J 1998; 39: 721-730.
35. Ito K, Date T, Ikegami M, et al. An immunohistochemical analysis of tissue thrombin expression in the human atria. PLoS One 2013; 8: e65817.
36. Lip GY, Patel JV, Hughes E, et al. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007; 38: 1229-1237.
37. Varon D, Shai E. Platelets and their microparticles as key players in pathophysiological responses. J Thromb Haemost 2015; 13 (Suppl 1): S40-S46.
38. Hayashi M, Takeshita K, Inden Y, et al. Platelet activation and induction of tissue factor in acute and chronic atrial fibrillation: involvement of mononuclear cell-platelet interaction. Thromb Res 2011; 128: e113-e118.
39. Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014; 129: 2094-2099.
40. Passacquale G, Vamadevan P, Pereira L, et al. Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLoS One 2011; 6: e25595.
41. Liuba I, Ahlmroth H, Jonasson L, et al. Source of inflammatory markers in patients with atrial fibrillation. Europace 2008; 10: 848-853.
42. Halonen J, Halonen P, Jarvinen O, et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. J Am Med Assoc 2007; 297: 1562-1567.
43. Kling D, Stucki C, Kronenberg S, et al. Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies. Thromb Res 2013; 131: 401-410.
44. Willecke F, Tiwari S, Rupprecht B, et al. Interruption of classic CD40L-CD40 signalling but not of the novel CD40L-Mac-1 interaction limits arterial neointima formation in mice. Thromb Haemost 2014; 112: 379-389.